Abstract
Differentiation is a term that indicates the degree to which a tumor resembles histologically the tissue or cell of origin. A system to quantitate the proportion of breast cancer cells participating in glandular differentiation or remaining within ducts was employed. The degree of tumor differentiation of 58 primary breast cancers was correlated with estrogen (ER) and progesterone receptors (PR) and tumor aromatase activity. There was a significant association between tumor differentiation (≥2% cancer cells exhibiting glandular differentiation) and the presence of ER or PR in tumors. Conversely, there was no correlation between tumor differentiation and measurable tumor aromatase activity.
References
Grodin JM, Siiteri PK, MacDonald PC: Source of estrogen productíon in postmenopausal women. J Clin Endocrinol Metab 36: 207–214, 1973
Poortman J, Thijssen JHH, Schwarz F: Androgen production and conversion to estrogen in normal postmenopausal women and in selected breast cancer patients. J Clin Endocrinol Metab 37: 101–109, 1973
Siiteri PK, Williams JE, Takaki NK: Steroid abnormalities in endometrial and breast carcinoma: A unifying hypothesis. J Steroid Biochem 7: 897–903, 1976
Longcope C: Methods and results of aromatization studies in vivo. Cancer Res 1982; (Suppl) 42: 3307s-3311s
Abul-Hajj YJ, Iverson R, Kiang DT: Aromatization of androgens by human breast cancer. Steroids 33: 205–221, 1979
Li K, Chandra DP, Foo T, Adams JB, McDonald D: Steroid metabolism by human mammary carcinoma. Steroids 28: 561–574, 1976
Miller WR, Forrest APM: Oestradiol synthesis from C19 steroids by human breast cancers. Br J Cancer 33: 116–118, 1976
Perel E, Wilkins D, Killinger DW: The conversion of androstenedione to estrone, estradiol and testosterone in breast tissue. J Steroid Biochem 13: 89–94, 1980
Varela RM, Dao TL: Estrogen synthesis and estradiol binding by human mammary tumors. Cancer Res 38: 2429–2433, 1978
Siiteri PK: Review of studies on estrogen biosynthesis in the human. Cancer Res (Suppl) 42: 3269s-3273s, 1982
Tilson-Mallett N, Santner SJ, Feil PD, Santen RJ: Biological significance of aromatase activity in human breast tumors. J Clin Endocrinol Metab 57: 1125–1128, 1983
Lipton A, Santner SJ, Santen RJ, Harvey HA, Feil PD, White-Hershey D, Bartholomew MJ, Antle CE: Aromatase activity in primary and metastatic human breast cancer. Cancer 59: 779–782, 1987
Sharkey FE, Pavlak RJ, Greiner AS: Morphometric analysis of differentiation in human breast carcinoma. Arch Pathol Lab Med 107: 406–410, 1983
Sharkey FE: Morphometric analysis of differentiation in human breast carcinoma. Arch Pathol Lab Med 107: 411–414, 1983
McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 37: 637–639, 1977
Feil PD, Klase JC, Margets MJ: Use of medroxyprogesterone acetate to measure cytosol progestin receptors in human breast cancer (Abstr). 61st Annual Meeting of The Endocrine Society, Anaheim, California 150: 1979
Thompson EA, Siiteri PK: Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 249: 5364–5372, 1974
Weisz J, Brown BL, Ward IL: Maternal stress decreases steroid aromatase activity in brains of male and female rat fetuses. Neuroendocrinology 35: 374–379, 1982
Chalkley HW: Method for the quantitative morphologic analysis of tissues. JNCI 4: 47–53, 1943
Wittliff JL, Hilf R, Brooks WF Jr, Savlov ED, Hall TC, Orlando RH: Specific estrogen-binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans. Cancer Res 32: 1983–1992, 1971
Johansson H, Terenius L, Thoren L: The binding of estradiol-17β to human breast cancers and other tissues in vitro. Cancer Res 30: 692–698, 1970
Terenius L, Johansson H, Rimsten A, Thoren L: Malignant and benign human mammary disease: Estrogen binding in relation to clinical data. Cancer 33: 1364–1368, 1974
Savlov ED: Correlations between certain biochemical properties of breast cancer and response to therapy: A preliminary report. Cancer 32: 303–309, 1973
Korenman SG, Dukes BA: Specific estrogen binding by the cytoplasm of human breast carcinoma. J Clin Endocrinol 30: 639–645, 1970
Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–377, 1957
Rich MA, Brennan MJ: The breast cancer prognostic program: A study of the metastatic process.In: Brennan MJ, McGrath CM, Rich MA (eds) Breast Cancer: New Concepts in Etiology and Control. Academic Press, New York, 1980; pp 29–51
Delides GS, Garas G, Georgouli Get al.: Intralaboratory variations in the grading of breast carcinoma. Arch Pathol Lab Med 106: 126–128, 1982
Rosen PP, Menendez-Botet CJ, Nisselbaum JSet al.: Pathologic review of breast lesions analyzed for estrogen receptor protein. Cancer Res 35: 3187–3194, 1975
Mohammed RH, Lakatua DJ, Haus E, Yasmineh WJ: Estrogen and progesterone receptors in human breast cancer — correlation with histologic subtype and degree of differentiation. Cancer 58: 1076–1081, 1986
Underwood JCE: A morphometric analysis of human breast carcinoma. Br J Cancer 26: 234–237, 1972
Faull TW, Feil PD, Sharkey FE: Correlation of estrogen receptor levels with histological differentiation of breast cancer — a morphometric analysis. Abstract, 5th Annual San Antonio Breast Cancer Symposium, Nov. 1982
Barry JD, Koch TJ, Cohen C, Brigati DJ, Sharkey FE: Correlation of immunohistochemical markers with patient prognosis in breast carcinoma. A quantitative study. Am J Clin Path 82: 582–585, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lipton, A., Santen, R.J., Santner, S.J. et al. Correlation of aromatase activity with histological differentiation of breast cancer — A morphometric analysis. Breast Cancer Res Tr 12, 31–35 (1988). https://doi.org/10.1007/BF01805737
Issue Date:
DOI: https://doi.org/10.1007/BF01805737